Researchers David Vanness and James Lomas joined the Bridge the City podcast to explain the conclusions of their new paper, “A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.” They describe how pharmaceutical products whose prices do not represent good value for money can adversely impact all Americans (e.g., employers giving fewer wage increases due to higher health insurance costs), and how innovators can suffer from poorly designed R&D incentives. Tune in here.
